Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Olezarsen sodium by Ionis Pharmaceuticals for Familial Chylomicronemia (Type I Hyperlipoproteinemia): Likelihood of Approval
Olezarsen sodium is under clinical development by Ionis Pharmaceuticals and currently in Pre-Registration for Familial Chylomicronemia (Type I Hyperlipoproteinemia). According...